Inactive Instrument

Clarus Therapeutics Holdings, Inc. Stock

CRXT

US18271L1070

Latest news : Clarus Therapeutics Holdings, Inc.

23-02-28	Clarus Therapeutics Holdings, Inc. Went Out of Business	CI
23-02-09	First Amended Combined Liquidation Plan and Disclosure Statement Approved for Clarus Therapeutics Holdings, Inc.	CI
23-01-16	First Motion for Exclusivity Period Extension Approved For Clarus Therapeutics Holdings, Inc.	CI
22-12-28	First Motion for Exclusivity Period Extension Filed by Clarus Therapeutics Holdings, Inc.	CI
22-12-22	First Amended Combined Liquidation Plan and Disclosure Statement Approved on Interim Basis for Clarus Therapeutics Holdings, Inc.	CI
22-12-21	First Amended Combined Liquidation Plan and Disclosure Statement Filed by Clarus Therapeutics Holdings, Inc.	CI
22-12-01	Combined Liquidation Plan and Disclosure Statement Filed by Clarus Therapeutics Holdings, Inc.	CI
22-10-31	Clarus Therapeutics Holdings, Inc. Announces Termination of Robert Dudley as Chief Executive Officer	CI
22-10-31	Clarus Therapeutics Holdings, Inc. Announces Termination of Steven Bourne as Chief Financial Officer, Effective November 14, 2022	CI
22-10-31	Clarus Therapeutics Holdings, Inc. Announces Executive Changes	CI
22-10-26	Motion for Asset Sale Approved for Clarus Therapeutics Holdings, Inc.	CI
22-09-22	Bidding Procedure Approved for Clarus Therapeutics Holdings, Inc.	CI
22-09-07	Motion for Joint Administration Approved for Clarus Therapeutics Holdings, Inc.	CI

More news

Analysts' recommendations: Clarus Therapeutics Holdings, Inc.

22-08-22	Needham & Co Downgrades Clarus Therapeutics to Hold From Buy	MT
22-08-22	Maxim Downgrades Clarus Therapeutics Holdings to Hold From Buy	MT
22-05-17	Truist Securities Adjusts Clarus Therapeutics Holdings' Price Target to $3 from $7, Keeps Buy Rating	MT
22-05-17	Needham & Co. Adjusts Price Target for Clarus Therapeutics to $3 From $8, Reiterates Buy Rating	MT
22-03-31	Cantor Fitzgerald Adjusts Clarus Therapeutics Holdings Piece Target to $3 From $20, Maintains Overweight Rating	MT

More recommendations

Press Releases: Clarus Therapeutics Holdings, Inc.

23-03-01	CLARUS THERAPEUTICS HOLDINGS, INC. : Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Other Events (form 8-K)	AQ
23-02-22	CLARUS THERAPEUTICS HOLDINGS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
23-01-24	CLARUS THERAPEUTICS HOLDINGS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
22-12-22	CLARUS THERAPEUTICS HOLDINGS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
22-11-23	CLARUS THERAPEUTICS HOLDINGS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ

More press releases

Managers and Directors: Clarus Therapeutics Holdings, Inc.

Manager	Title	Age	Since
Jay Newmark CTO	Chief Tech/Sci/R&D Officer	-	-
Kara Stancell IRC	Investor Relations Contact	-	-
Lawrence Perkins PRN	Corporate Officer/Principal	49	-

More insiders

Clarus Therapeutics Holdings, Inc. is a pharmaceutical company. The Company is engaged in the development of androgen-based medicines. The Company is focused on the commercialization of JATENZO, which is an oral testosterone replacement or testosterone replacement therapy (TRT). JATENZO is a created by the linkage of T with the fatty acid undecanoic acid to form testosterone undecanoate. JATENZO is developed for T-replacement therapy to treat adult men with hypogonadism due to certain medical conditions. It also focuses on the signs and symptoms associated with hypogonadism such as psychosexual symptoms, body mass index, fat mass and bone mineral density. The Company's subsidiary is Clarus Therapeutics, Inc.

Employees

Sector

Pharmaceuticals

More about the company

Stock Market
Stocks
CRXT Stock

The best tools reserved for subscribers to boost the performance of your investments!

Date	Insider	Type	Main position	Quantity	% Market Cap.
6/7/22	Elizabeth Cermak	Free	Director	6,727	0.0129%
6/7/22	John Amory	Free	Director	6,727	0.0129%
6/7/22	Blue Water Sponsor LLC	Other	Company	0	0%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CLARUS THERAPEUTICS HOLDINGS, INC.	-.--%	-.--%	-	-	72.83K
ELI LILLY AND COMPANY	+0.21%	+4.98%	+48.99%	+164.62%	1,067B
JOHNSON & JOHNSON	+1.49%	+7.66%	+61.15%	+54.22%	635B
ABBVIE INC.	+0.47%	+2.97%	+38.40%	+75.29%	458B
ROCHE HOLDING AG	+1.70%	+8.80%	+38.49%	+32.46%	347B
NOVARTIS AG	+1.62%	+4.96%	+38.42%	+42.37%	295B
ASTRAZENECA PLC	+2.25%	+4.57%	+19.98%	+20.99%	262B
NOVO NORDISK A/S	+2.02%	-0.17%	-27.42%	-38.47%	216B
AMGEN INC.	+0.89%	+4.88%	+26.77%	+61.80%	203B
GILEAD SCIENCES, INC.	+2.03%	-0.29%	+17.51%	+73.60%	161B
Average	+1.32%	+1.33%	+29.14%	+54.10%	404.83B
Weighted average by Cap.	+1.15%	+1.95%	+38.68%	+79.55%

Clarus Therapeutics Holdings, Inc. Stock

Stocks